Tailoring combinatorial cancer therapies to target the origins of adaptive resistance.
The development of resistance to chemotherapy is a critical yet poorly understood phenomenon driving cancer-related deaths. We recently reported a study that explored the origins of adaptive chemotherapy resistance. During this investigation we unexpectedly discovered that inherent vulnerabilities were unmasked, creating temporal targets for rational combinations of established drugs.
Department of Medicine, Harvard Medical School; Brigham and Women's Hospital; Division of Biomedical Engineering ; Cambridge, MA USA.
Aaron
A
Goldman
adaptive resistance; cancer stem cells; computational biology; mathematical modeling; tumor heterogeneity